Profusa, Inc. - Common Stock (PFSA)

Nika Pharmaceuticals, Inc. (OTCQB: NIKA ) is gaining investor attention as a next-generation biopharmaceutical company developing advanced immune-strengthening therapeutics for some of the world’s most critical diseases, including HIV/AIDS, Hepatitis B and C, Rheumatoid Arthritis, Cancer, and Diabetes .

The autonomous vehicle revolution has officially moved beyond concept and into real-world deployment. In major U.S. cities including Phoenix, San Francisco, Los Angeles, and Austin, fully driverless robotaxi fleets operated by Waymo, Cruise, and Tesla are already transforming urban mobility.

New note provides greater repayment flexibility and less dilution with elimination of mandatory amortization payments, increased conversion floor price to $0.35, and expanded mandatory ELOC payments from 33% to 50%

As year-end positioning accelerates, the traditional Santa’s Rally is shining a spotlight on small-cap and micro-cap stocks under $5 showing renewed momentum, rising volume, and investor awareness. These names are drawing attention across technology, fintech, media, space, and consumer sectors—areas where speculative capital often rotates during holiday trading weeks.

Data from FDA-advised study demonstrates Lumee™ Oxygen tissue monitoring is a safe and effective long-term method in PAD patients and will support potential FDA submission; strongly correlates with transcutaneous partial pressure of oxygen

Study conducted at US sites evaluates LumeeTM in peripheral artery disease (PAD) patients

Study evaluates Lumee™ Oxygen tissue monitoring platform with transcutaneous partial pressure of oxygen (tcpO₂) in peripheral artery disease patients

Recapitalization reduced net debt to $14 million as of October 31; achieved key milestones to deliver potential 2026 revenue target

EU commercialization expected in early 2026; U.S. entry and expanded indications to follow as digital-health pioneer advances tissue-integrated biosensor platform

Signal Advance, Inc. (OTC: SIGL ) today announced a new milestone in the evolution of cybersecurity: successful validation of its Analog Guard® encryption platform as resistant to advanced artificial intelligence (AI) decryption models. The breakthrough supports Signal Advance’s mission to deliver next-generation, physics-based cybersecurity solutions designed to defend against both AI-driven and quantum-era threats. Listen to CEO Now!

Achieved key operational milestones establishing manufacturing capabilities to supply more than 2x the products required to achieve 2026 revenue targets

Initial target markets for commercialization include Germany, the Benelux countries, Austria, the United Kingdom, and Scandinavia

Initial target markets for commercialization include Germany, the Benelux countries, Austria, the United Kingdom, and Scandinavia

BERKELEY, Calif, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual’s biochemistry, announces its second $1 million investment in digital treasury assets to hedge against macroeconomic uncertainties, in line with the Company’s treasury management strategy.